Kesofast

PPIs are possibly associated with increased incidence of Clostridium difficile- associated diarrhoea.
May decrease the efficacy of clopidogrel by reducing the formation of active metabolite.
Sever hepatic impairment.
Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus.

PHARMACOKINETICS
Absorption: after oral administration, peak plasma levels (Cmax) occur at approximately 1.5 hours (Tmax).
Protein binding: 97%
Half life: 1-1.5hr
Metabolism: extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system.
Excretion: less than 1% of parent drug is excreted in the urine.

PHARMACODYNAMIC
Esomeprazole with its dual action exerts its stomach acid-suppressing effects. It covalently binds to and blocks the (H+/K+) ATPase/ Proton pump at the secretory surface of gastric parietal cells. Also contains Sodium bicarbonate, it act as a antacid itself in the stomach neutralizing HCl locally followed by the action of PPI through parietal cells resulting to inhibition of both basal and stimulated gastric acid.

Gastroesophageal reflux disease, healing of erosive esophagitis: 20mg or 40 mg once daily for 4 to 8 weeks.
Maintenance of healing of erosive oesophagitis: 20mg once daily.
Symptomatic gastroesophageal reflux: 20mg once daily for 4 weeks.
H. Pylori eradication to reduce the risk of duodenal ulcer recurrence: 40 mg daily

Bad, unusual or unpleasant(after) taste, drowsiness, bloating, constipation, fast heart beat, indigestion, nausea, seizures, skin rash, hives, sore throat & vomiting.